Predose Infant Nevirapine Concentration With the Two-Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine Dose

Mark Mirochnick(Boston University), John L. Sullivan, Coleen K. Cunningham(Duke Medical Center), Alejandro Dorenbaum(University of California, San Francisco), Mary Culnane(National Institute of Allergy and Infectious Diseases), Suzette Blanchard(Rutgers, The State University of New Jersey), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Richard D. Gelber(Harvard University)
JAIDS Journal of Acquired Immune Deficiency Syndromes
June 1, 2003
10.1097/00126334-200306010-00006
Cited by 44

Related Papers

Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis
|BMJ|2020|2.4k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k